Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 12Recurrence 4Lymphoma, Non-Hodgkin 4Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma 2Hematologic Neoplasms 2Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia 1Burkitt Lymphoma 1

Interventions

Rituximab 82venetoclax 56ibrutinib 46obinutuzumab 43Bendamustine Hydrochloride 40idelalisib 30Cyclophosphamide 29acalabrutinib 28fludarabine 27Chlorambucil 27pirtobrutinib 18ublituximab 16ofatumumab 16zanubrutinib 14umbralisib 14Lenalidomide 11fludarabine phosphate 9Alemtuzumab 9navitoclax 7duvelisib 7Azacitidine 5lumiliximab 4aflibercept 4TRU 016 4Interleukin-2 4BI 836826 4ARQ531 4tafasitamab 3motexafin gadolinium 3dinaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Lymphocytic, Chronic, B-Cell × tafasitamab × Clear all
NCT04809467 2026-02-04

topMIND

Incyte Corporation

Phase 1/2 Terminated
54 enrolled 23 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02639910 2021-12-20

COSMOS

MorphoSys AG

Phase 2 Completed
24 enrolled 13 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01161511 2014-04-21

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Xencor, Inc.

Phase 1 Completed
27 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡